Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12125157 | 0.90 | ELANE (0.48) | ELANEPOLBKMT2ASMN1; SMN2HTT | |
| SCHEMBL4804779 | 0.88 | ELANE (0.64) | ELANEPOLBKMT2ASMN1; SMN2HTT | |
| SCHEMBL4544913 | 0.86 | ELANE (0.61) | ELANEPOLBKMT2ASMN1; SMN2HTT | |
| SCHEMBL24157306 | 0.86 | ELANE (0.61) | ELANEPOLBKMT2ASMN1; SMN2HTT | |
| SCHEMBL25500917 | 0.85 | ELANE (0.51) | ELANEPOLBKMT2ASMN1; SMN2HTT | |
| SCHEMBL29127198 | 0.83 | KMT2A (0.71) | ELANEPOLBKMT2ASMN1; SMN2HTT | |
| SCHEMBL26038607 | 0.83 | KMT2A (0.69) | ELANEPOLBKMT2ASMN1; SMN2HTT | |
| SCHEMBL10932380 | 0.82 | ELANE (0.48) | ELANEPOLBKMT2ASMN1; SMN2HTT | |
| SCHEMBL10932384 | 0.82 | ELANE (0.48) | ELANEPOLBKMT2ASMN1; SMN2HTT | |
| SCHEMBL25502752 | 0.82 | ELANE (0.48) | ELANEPOLBKMT2ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630902-B2 | Method of preparing fused ring indeno compounds | TRANSITIONS OPTICAL, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160209561-A1 | Photochromic Articles That Include Photochromic-Dichroic Materials | TRANSITIONS OPTICAL, INC. | 2016-07-21 | — | — | US | disclosed |
| EP-3045971-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | Transitions Optical, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9334439-B2 | Photochromic articles that include photochromic-dichroic materials | TRANSITIONS OPTICAL, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| EP-2652553-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20160060205-A1 | Method Of Preparing Fused Ring Indeno Compounds | TRANSITIONS OPTICAL, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9206151-B2 | Method of preparing fused ring indeno compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9051332-B1 | Photochromic indeno-fused ring pyran compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2015077141-A1 | FUSED RING INDENO COMPOUNDS FOR PREPARATION OF PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077147-A1 | METHOD OF PREPARING FUSED RING INDENO COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077264-A1 | PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20150141661-A1 | Photochromic Indeno-Fused Ring Pyran Compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141662-A1 | Method Of Preparing Fused Ring Indeno Compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141663-A1 | Fused Ring Indeno Compounds For Preparation Of Photochromic Compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-9029565-B1 | Fused ring indeno compounds for preparation of photochromic compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140272468-A1 | PHOTOCHROMIC ARTICLES THAT INCLUDE PHOTOCHROMIC-DICHROIC MATERIALS | TRANSITIONS OPTICAL, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8582192-B2 | Polarizing photochromic articles | TRANSITIONS OPTICAL, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8518546-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2013-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141662-A1 | Method Of Preparing Fused Ring Indeno Compounds | INHA, INTS9, CA9 | ELANE 1528/4885POLB 4370/4885KMT2A 1445/4885 |
| US-20150141663-A1 | Fused Ring Indeno Compounds For Preparation Of Photochromic Compounds | IPO5, INCENP, NQO1 | ELANE 3355/4885POLB 1002/4885KMT2A 1702/4885 |
| US-20160060205-A1 | Method Of Preparing Fused Ring Indeno Compounds | INHA, INTS9, CA9 | ELANE 1528/4885POLB 4370/4885KMT2A 1445/4885 |
| US-20150141661-A1 | Photochromic Indeno-Fused Ring Pyran Compounds | INF2, INCENP, RB1 | ELANE 3243/4885POLB 2843/4885KMT2A 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.